AVEO Oncology, an LG Chem company, team members returned from the recent KidneyCAN #KCRS24 symposium feeling inspired and encouraged for patients! Attending alongside them were many industry peers and key opinion leaders who presented the latest research and treatment data in the kidney cancer community. #oncology #pharma #biotech #kidneycancer #acceleratingcures
AVEO Oncology
Biotechnology Research
Boston, Massachusetts 21,209 followers
Committed to delivering medicines that provide a better life for patients with cancer.
About us
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
- Website
-
http://www.aveooncology.com
External link for AVEO Oncology
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2001
- Specialties
- Oncology
Locations
-
Primary
30 Winter St
3rd Floor
Boston, Massachusetts 02108, US
Employees at AVEO Oncology
Updates
-
AVEO Oncology, an LG Chem company, today announced the topline results of the TiNivo-2 Phase 3 trial, which was designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab, as compared to tivozanib as a monotherapy, in renal cell carcinoma (RCC) patients whose tumors have progressed following prior immune checkpoint inhibitor therapy. Detailed findings are expected to be presented at an upcoming medical meeting. For more information, read the full press release here: https://lnkd.in/eqBhURte
-
AVEO Oncology, an LG Chem company, wishes everyone a happy and safe #4thofJuly.
-
Mike Ferraresso, Chief Commercial Officer, AVEO Oncology, an LG Chem company, recently shared valuable insights and the latest trends in customer engagement as a panelist at the Axtria - Ingenious Insights Ignite 2024 Conference. The seminar, entitled “The Evolution of the Customer Engagement Models to Achieve Greater Customer Centricity,” explored how the life sciences industry can best serve customers in times of challenging access and unique local market dynamics. #AxtriaIGNITE #Pharma #Lifsciences #Leadership #oncology #biotech
-
AVEO Oncology, an LG Chem company, joins the International Kidney Cancer Coalition (IKCC) for #WorldKidneyCancerDay 2024 today, June 20th, to call attention to the 431,000 people worldwide diagnosed with #kidneycancer every day, and applauds IKCC in its mission to empower the kidney cancer community through advocacy, awareness, information, and research.
-
Today we commemorate #Juneteenth and the emancipation of enslaved African Americans. Join us in learning, engaging, and supporting initiatives that promote racial justice and equality. AVEO Oncology, an LG Chem company, is committed to a diverse, inclusive, and equitable future.
-
AVEO Oncology, an LG Chem company, honors the FDA Oncology Center of Excellence National Black Family Cancer Awareness week June 13th through June 19th. During this time, we acknowledge the challenges faced by black families affected by cancer and share our support by raising awareness. #oncology #pharma #biotech #blackfamcan
-
LG Chem and AVEO Oncology, an LG Chem company, announced today that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109, LG Chem’s first proprietary anti-cancer investigational drug candidate, a next-generation immune checkpoint inhibitor. LG Chem will be collaborating closely with AVEO, a wholly owned subsidiary of LG Chem, that specializes in oncology development and commercialization. The study is a Phase 1, multi-center, open-label, non-randomized, dose escalation study designed to determine the recommended Phase 2 dose of LB-LR1109, and to evaluate the safety and tolerability of the investigational drug in participants with advanced or metastatic solid tumors. Learn more here: https://lnkd.in/eyPi2B4k
LG Chem company and AVEO Oncology Announce LG Chem’s First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.
https://www.aveooncology.com
-
This June, AVEO Oncology, an LG Chem company, honors the 37th annual #NationalCancerSurvivorsDay (June 2nd) as well as the American Association for Cancer Research’s #NationalCancerSurvivorMonth. During this time, we would like to recognize all cancer patients, as AVEO remains focused and committed to providing innovative solutions to improve their lives.
-
This #MemorialDay and throughout the year, AVEO Oncology, an LG Chem company, remembers and honors the brave U.S. military men and women who made the ultimate sacrifice to protect our country and freedoms.